Navigation Links
ShangPharma Announces Second Quarter 2011 Results
Date:8/22/2011

uted earnings per ADS were $0.25, compared with $0.28 in the second quarter of 2010. The decrease is primarily due to the increase of weighted average outstanding ADSs as a result of our initial public offering in October 2010.
  • Total number of customers increased to 316 as of June 30, 2011 from 237 as of December 31, 2010 and 282 as of March 31, 2011.
  • The Company reaffirms its revenues, non-GAAP gross margin and capital expenditure guidance for the full year of 2011.

  • Management CommentMichael Xin Hui, founder and Chief Executive Officer of ShangPharma, commented, "We are pleased to deliver another quarter of broad-based solid results. Our business lines grew as a result of our strategy to expand our technology platforms and customer base in different geographical areas to respond to the demands of our clients.

    "Our expanded integrated service offerings are allowing us to penetrate deeper into our existing customer base. We are successfully attracting new customers in the Chinese pharmaceutical industry, which is a nascent, but rapidly growing industry.  Revenues from our China-based customers rose by 202.7% year-over-year, and included a mix of both local pharmaceutical companies and smaller domestic laboratories, as well as major multi-national biotech and pharmaceutical companies' R&D centers in China, representing a great improvement on the diversification of our customer base.  Revenue from China-based customers increased to near 10% of total revenues due to strong demand from the local market. There is tremendous growth opportunity for our services in China, and we plan to further increase our China business while simultaneously increasing penetration to developed pharmaceutical markets.  We continue to do very well in terms of generating revenues from our top customers, which are largely major global pharmaceutical and biotechnology companies. We have continued to benefit from the trend that big major gl
    '/>"/>

    SOURCE ShangPharma Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

    Related biology technology :

    1. ShangPharma Corporation Named a Top Ten Chinese Outsourcing Enterprise
    2. ShangPharma Announces First Quarter 2011 Results
    3. ShangPharma Corp. to Announce Fourth Quarter and Full Year 2010 Financial Results on March 15, 2011
    4. Stem Cell Assurance, Inc. Announces Change of Name to BioRestorative Therapies, Inc.
    5. Syndax Pharmaceuticals Announces Issuance of EU Patent for Entinostat
    6. Regeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA
    7. ACMG Announces New Online Live Learning Center: Will Bring Genetics and Genomics Education to Varied Health Professionals
    8. Neurologix Announces Second Quarter 2011 Financial Results
    9. Bion Announces New U.S. Patent for Phosphorus Removal
    10. ViaCyte Announces Executive Management Changes
    11. NeoStem Announces the Receipt of Over $1,700,000 in DOD Funding for its VSEL™ Technology Being Developed to Treat Osteoporosis
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/28/2015)... May 28, 2015 Clinerion, ... Basel, Switzerland, and the Alliance for Clinical ... Massachusetts-based non-profit organization operating in the public ... system to enhance quality, safety, integrity and ... health research, are pleased to announce their ...
    (Date:5/27/2015)... , May 27, 2015 RXi Pharmaceuticals ... focused on discovering and developing innovative therapies primarily ... that it has commenced a public offering of ... shares of its common stock and overallotment purchase ... The shares of common stock, warrants and overallotment ...
    (Date:5/27/2015)... 26, 2015 Research and Markets( http://www.researchandmarkets.com/research/8nqqdw/global_breast ... "Global Breast Cancer Monoclonal Antibodies Market Outlook 2020" ... Roche seems to dominate the breast cancer monoclonal ... buster molecule, Herceptin has been able to dominate ... that breast cancer cells become recalcitrant and relapsed ...
    (Date:5/27/2015)... (PRWEB) May 27, 2015 Expanding in ... cement manufacturer Avalon Biomed Inc. recently inked ... Mokuda Dental Co. Ltd. , the largest endodontic ... into the international market for Avalon Biomed, which manufactures ... award-winning tricalcium silicate-based dental cements that have won renown ...
    Breaking Biology Technology:Clinerion and ACRES Partner on Patient Recruitment and Risk-Based Quality Management 2Clinerion and ACRES Partner on Patient Recruitment and Risk-Based Quality Management 3RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 3Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 2Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 3Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 2Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 3
    ... , , FT. LAUDERDALE, ... Bulletin Board: ISPI) announced today an important development within the ... technology of Integral Bioenergies Systems, SL (IBS). This firm has ... treatment of biomass/sludge obtained at sewage treatment plants. , IBS ...
    ... Feb. 5 Novavax, Inc. (Nasdaq: NVAX ) a ... and Chief Executive Officer of Novavax will be presenting at the 12th ... at 10:00 am local time. Hosted by the Biotechnology Industry ... place February 8-9 at the Waldorf = Astoria, New ...
    ... , LONDON and PALO ALTO, Calif. ... plc (AIM: SLN) today announced that Philip Haworth , Ph.D., chief ... 12th Annual BIO CEO & Investor Conference.  The conference will be held ... York City . , Silence,s presentation will take place at 11:00 ...
    Cached Biology Technology:InfoSpi Shall Benefit From Contract for Future Use of IBS Technology 2NOVAVAX to Present at the 12th Annual BIO CEO & Investor Conference 2Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference 2Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference 3
    (Date:5/19/2015)... -- Fingerprint Cards (FPC) has received an order ... FPC1035 from one if its module partners. Deliveries are planned ... and the sensors will be used by smartphone manufacturers in ... hereby amount to 740 MSEK to date. In addition to ... a number of smaller orders not separately communicated amounting to ...
    (Date:5/14/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ... Sensors Market in Smart Mobile Devices " report ... 2014 was a watershed year for fingerprint sensors in ... Pay,. Apple gave fingerprint sensors a raison d,etre in ... sensors are a must-have feature in flagship smartphones. ...
    (Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
    Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
    ... that some biological structures, like the brain or the ... explain. Biologists have proposed various ways that so-called ,irreducibly ... bit. But a new study proposes an alternative route. ... becoming more intricate, say authors Dan McShea and Wim ...
    ... Ohio American adults who prepare their own meals and ... on one of those activities at the expense of the ... a 10-minute increase in food preparation time was associated with ... for both men and women. The finding applied to single ...
    ... helpers (nannies) in a cichlid fish allow the dominant male ... and territory, according to new research published today in ... 30 days which corresponds to one breeding cycle in ... and the University of Bern (Switzerland) studied the investment strategies ...
    Cached Biology News:Study proposes alternative way to explain life's complexity 2Study proposes alternative way to explain life's complexity 3Exercise or make dinner? Study finds adults trade one healthy act for another 2Exercise or make dinner? Study finds adults trade one healthy act for another 3
    Blank Calibration Particles, 3.0-3.4 mu m 5 ml...
    Alexa Fluor 647 anti-mouse IL-12 (Interleukin-12) / IL-23 (Interleukin-23) p40 25 ug...
    MAb to Transferrin Dry Ice: No Preservative: NaN3 Availability When Not in Inventory: 14-21 Business Days...
    Rabbit polyclonal to IRS1 (phospho S636) ( Abpromise for all tested applications). entrezGeneID: 3667 SwissProtID: P35568...
    Biology Products: